An interventional study of Surgical Atrial Fibrillation Ablation in Atrial Fibrillation and Heart Failure, sponsored by Population Health Research Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Population Health Research Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Atrial Fibrillation by Population Health Research Institute — 6 open to participants now, 6 under way, 1 of them phase 3. Atrial Fibrillation · Population Health Research Institute.
Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 7 with no phase, and was the 25th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 30 studies in Atrial Fibrillation by Population Health Research Institute are open now, in 12 countries. Recruiting first, the newest first:
Population Health Research Institute · Sites in United States, Austria, Canada and 2 more countries
Ages 18+
Population Health Research Institute · Sites in Canada
Ages 18–120
Population Health Research Institute · Sites in Canada
Ages 18+
Population Health Research Institute · Sites in United States, Argentina, Australia and 15 more countries
Ages 55+
Population Health Research Institute
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 24 interventional studies, 253 across the 6 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
3 of the studies in Atrial Fibrillation by Population Health Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011095Population Health Research InstituteDOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial | 2027-02-03 |
| NCT06486636Population Health Research InstitutePericardiotomy in Cardiac Surgery | 2027-09-01 |
| NCT05434819Population Health Research InstituteSurgical Ablation of AF Efficacy Trial | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.
Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.
Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.
The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing any of the following procedures:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.
Procedure: Surgical Atrial Fibrillation Ablation
Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.
Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
Number of hospital readmissions for heart failure over duration of follow-up
Total number of hospital readmissions for heart failure.
Time frame: Common termination point for trial (median follow-up of 4 years)
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
Time frame: Common termination point for trial (median follow-up of 4 years)
Length of ICU stay
Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions
Time frame: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Length of hospital stay
Length of hospital stay
Time frame: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Freedom from recurrence of atrial tachyarrhythmia
Freedom from recurrence of atrial tachyarrhythmia
Time frame: 1 year post-operatively
Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure
Number of days free admission to healthcare facility or presentation to the emergency department for heart failure
Time frame: Common termination point for trial (median follow-up of 4 years)
All-cause mortality
All-cause mortality
Time frame: Common termination point for trial (median follow-up of 4 years)
Cardiovascular mortality
Cardiovascular mortality
Time frame: Common termination point for trial (median follow-up of 4 years)
Antiarrhythmic drug use
Antiarrhythmic drug use
Time frame: Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
Number of patients undergoing atrial fibrillation ablation
Number of patients undergoing atrial fibrillation ablation
Time frame: 90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
Quality of Life - atrial fibrillation specific
Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome.
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - heart failure specific
Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome.
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - General
Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of Ischemic stroke and systemic arterial embolism
Safety outcome
Time frame: Up to 30 days post-operatively
Number of patients requiring permanent pacemaker implantation
Safety outcome
Time frame: Up to 1 year post-operatively
Volume of chest tube output
Safety outcome - chest tube output measured in mL.
Time frame: Up to 24 hours post-operatively
Re-operation for bleeding
Safety outcome
Time frame: From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
All-cause mortality
Safety outcome
Time frame: Prior to discharge or within 30 days post-operatively (whichever occurs first)
Post-operative major bleeding
Safety outcome
Time frame: <48 hours after surgery
Number of patients with pulmonary vein stenosis
Safety outcome
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with stiff left atrium syndrome
Safety outcome
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with esophageal to atrial fistula
Safety outcome
Time frame: At 1 year, and at common termination point for trial (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Economic analysis will be assessed via health care utilization by patients
Time frame: At 1 year, and at common termination point (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients.
Time frame: At 1 year, and at common termination point (median follow-up of 4 years)
Started Jun 2023 (actual). Primary completion is estimated for Sep 2027, 51 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 51 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Population Health Research Institute →